Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marije B Overdijk

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Blood Cancer Journal|October 6, 2025
Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCLHilma J van der Horst, Tamás Csikós, Marjolein Quik, et al.
Molecular Cancer Therapeutics|August 28, 2020
Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 AgonismMarije B Overdijk, Kristin Strumane, Frank J Beurskens, et al.
Clinical and Translational Science|May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed HepatotoxicityMarije B Overdijk, Kristin Strumane, Ruth Plummer, et al.
Blood Cancer Journal|April 29, 2020
DuoHexaBody-CD37<sup>®</sup>, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignanciesSimone C Oostindie, Hilma J van der Horst, Laurens P Kil, et al.
Molecular Cancer Therapeutics|June 30, 2026
Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability TradeoffsLouise A Koopman, Farshid Alemdehy, Stefanie A H de Poot, et al.
Journal for Immunotherapy of Cancer|July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphomaFarrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Blood Cancer Journal|October 6, 2025
Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCLHilma J van der Horst, Tamás Csikós, Marjolein Quik, et al.
Molecular Cancer Therapeutics|August 28, 2020
Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 AgonismMarije B Overdijk, Kristin Strumane, Frank J Beurskens, et al.
Clinical and Translational Science|May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed HepatotoxicityMarije B Overdijk, Kristin Strumane, Ruth Plummer, et al.
Blood Cancer Journal|April 29, 2020
DuoHexaBody-CD37<sup>®</sup>, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignanciesSimone C Oostindie, Hilma J van der Horst, Laurens P Kil, et al.
Molecular Cancer Therapeutics|June 30, 2026
Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability TradeoffsLouise A Koopman, Farshid Alemdehy, Stefanie A H de Poot, et al.
Journal for Immunotherapy of Cancer|July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphomaFarrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.
Pageof 2